Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Psoriatic | 14 | 2020 | 625 | 3.28 | Why? |
| Arthritis, Rheumatoid | 22 | 2021 | 2043 | 3.07 | Why? |
| Patient Reported Outcome Measures | 9 | 2020 | 912 | 2.28 | Why? |
| Spondylarthritis | 6 | 2020 | 174 | 2.18 | Why? |
| Antirheumatic Agents | 20 | 2021 | 3023 | 1.93 | Why? |
| Psychometrics | 5 | 2019 | 1269 | 1.11 | Why? |
| Remission Induction | 6 | 2020 | 950 | 0.92 | Why? |
| Sickness Impact Profile | 1 | 2020 | 56 | 0.87 | Why? |
| Fatigue | 5 | 2020 | 2479 | 0.84 | Why? |
| Rheumatology | 12 | 2021 | 1213 | 0.84 | Why? |
| Axis, Cervical Vertebra | 2 | 2017 | 12 | 0.76 | Why? |
| Adalimumab | 2 | 2019 | 389 | 0.71 | Why? |
| Quality of Life | 12 | 2020 | 9820 | 0.66 | Why? |
| Health Surveys | 2 | 2018 | 2841 | 0.64 | Why? |
| Low Back Pain | 1 | 2019 | 190 | 0.63 | Why? |
| Tumor Necrosis Factor-alpha | 6 | 2018 | 2483 | 0.61 | Why? |
| Etanercept | 1 | 2017 | 162 | 0.60 | Why? |
| Foot Dermatoses | 1 | 2017 | 112 | 0.59 | Why? |
| Nail Diseases | 1 | 2017 | 142 | 0.54 | Why? |
| Rheumatic Diseases | 8 | 2021 | 2675 | 0.51 | Why? |
| Hand Dermatoses | 1 | 2017 | 284 | 0.48 | Why? |
| Fear | 2 | 2018 | 3607 | 0.48 | Why? |
| Cost of Illness | 2 | 2020 | 1903 | 0.42 | Why? |
| Chronic Pain | 1 | 2019 | 736 | 0.42 | Why? |
| Social Behavior | 2 | 2020 | 882 | 0.42 | Why? |
| Severity of Illness Index | 15 | 2021 | 48226 | 0.37 | Why? |
| Pain Measurement | 3 | 2019 | 533 | 0.32 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.29 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.28 | Why? |
| Clinical Trials as Topic | 6 | 2019 | 7330 | 0.28 | Why? |
| Psoriasis | 2 | 2020 | 1739 | 0.27 | Why? |
| Sleep | 1 | 2017 | 2695 | 0.27 | Why? |
| Adaptation, Psychological | 4 | 2020 | 4996 | 0.26 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 9335 | 0.25 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.25 | Why? |
| Surveys and Questionnaires | 6 | 2019 | 43792 | 0.24 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.24 | Why? |
| France | 5 | 2019 | 12074 | 0.24 | Why? |
| Terminology as Topic | 2 | 2018 | 546 | 0.24 | Why? |
| Minimal Clinically Important Difference | 2 | 2020 | 39 | 0.23 | Why? |
| Musculoskeletal Diseases | 2 | 2020 | 646 | 0.23 | Why? |
| Spondylitis, Ankylosing | 2 | 2017 | 231 | 0.23 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.22 | Why? |
| Anti-Inflammatory Agents | 2 | 2018 | 6153 | 0.22 | Why? |
| Pelvimetry | 1 | 2020 | 1 | 0.21 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.21 | Why? |
| Sacroiliitis | 1 | 2020 | 24 | 0.21 | Why? |
| Treatment Outcome | 11 | 2020 | 51732 | 0.20 | Why? |
| Cross-Cultural Comparison | 2 | 2018 | 338 | 0.19 | Why? |
| Uveitis, Anterior | 1 | 2018 | 71 | 0.18 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.17 | Why? |
| Janus Kinase Inhibitors | 2 | 2020 | 682 | 0.17 | Why? |
| Enthesopathy | 1 | 2017 | 21 | 0.17 | Why? |
| Cultural Characteristics | 1 | 2018 | 159 | 0.17 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 229 | 0.17 | Why? |
| Joints | 1 | 2018 | 97 | 0.17 | Why? |
| Drug Substitution | 2 | 2017 | 385 | 0.16 | Why? |
| Demyelinating Diseases | 1 | 2018 | 224 | 0.15 | Why? |
| Male | 25 | 2021 | 367725 | 0.15 | Why? |
| Sick Leave | 1 | 2019 | 318 | 0.15 | Why? |
| Triazoles | 1 | 2020 | 440 | 0.15 | Why? |
| Factor Analysis, Statistical | 1 | 2018 | 538 | 0.15 | Why? |
| Female | 25 | 2021 | 380317 | 0.15 | Why? |
| Humans | 51 | 2021 | 930598 | 0.15 | Why? |
| Reproducibility of Results | 5 | 2020 | 11304 | 0.15 | Why? |
| Cross-Sectional Studies | 8 | 2019 | 53120 | 0.15 | Why? |
| Adult | 19 | 2020 | 244371 | 0.15 | Why? |
| Health Status Indicators | 1 | 2019 | 341 | 0.15 | Why? |
| Stress, Psychological | 2 | 2018 | 10231 | 0.15 | Why? |
| Fibromyalgia | 1 | 2017 | 174 | 0.15 | Why? |
| Blood Sedimentation | 1 | 2017 | 508 | 0.14 | Why? |
| Toes | 1 | 2017 | 252 | 0.14 | Why? |
| Radiography | 2 | 2020 | 1576 | 0.14 | Why? |
| Fingers | 1 | 2017 | 221 | 0.14 | Why? |
| Sweden | 2 | 2019 | 1969 | 0.13 | Why? |
| Pyridines | 1 | 2020 | 680 | 0.13 | Why? |
| Pain | 2 | 2020 | 1084 | 0.13 | Why? |
| Glucocorticoids | 5 | 2021 | 4431 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Self-Management | 1 | 2019 | 546 | 0.13 | Why? |
| Patient Participation | 2 | 2017 | 829 | 0.13 | Why? |
| Decision Making | 2 | 2017 | 3132 | 0.12 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.12 | Why? |
| Multivariate Analysis | 2 | 2020 | 5440 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Morbidity | 1 | 2016 | 1426 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Aged | 13 | 2021 | 215776 | 0.10 | Why? |
| Methotrexate | 3 | 2018 | 471 | 0.10 | Why? |
| Registries | 4 | 2021 | 12327 | 0.09 | Why? |
| Netherlands | 1 | 2018 | 3533 | 0.09 | Why? |
| Qualitative Research | 2 | 2018 | 4337 | 0.09 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Self Report | 1 | 2019 | 3802 | 0.08 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.08 | Why? |
| Feasibility Studies | 1 | 2016 | 3467 | 0.08 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.08 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.08 | Why? |
| Singapore | 1 | 2016 | 3641 | 0.08 | Why? |
| Longitudinal Studies | 3 | 2017 | 9893 | 0.08 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.07 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.07 | Why? |
| Mobile Applications | 1 | 2019 | 3032 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Consensus | 4 | 2019 | 6345 | 0.06 | Why? |
| Portugal | 2 | 2018 | 1265 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2020 | 6551 | 0.06 | Why? |
| Anxiety | 2 | 2019 | 17311 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2020 | 3893 | 0.06 | Why? |
| Germany | 1 | 2018 | 9196 | 0.06 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.05 | Why? |
| Orientation, Spatial | 1 | 2020 | 2 | 0.05 | Why? |
| Pelvic Bones | 1 | 2020 | 26 | 0.05 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.05 | Why? |
| Least-Squares Analysis | 1 | 2020 | 254 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Spain | 1 | 2018 | 15545 | 0.05 | Why? |
| Prostaglandins A | 1 | 2018 | 1 | 0.05 | Why? |
| HLA-B27 Antigen | 1 | 2018 | 48 | 0.05 | Why? |
| Exercise | 1 | 2019 | 6771 | 0.05 | Why? |
| Postural Balance | 1 | 2020 | 144 | 0.05 | Why? |
| Back Pain | 1 | 2020 | 115 | 0.05 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.05 | Why? |
| Translations | 1 | 2019 | 153 | 0.05 | Why? |
| Lumbar Vertebrae | 1 | 2020 | 196 | 0.04 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| C-Reactive Protein | 3 | 2018 | 7972 | 0.04 | Why? |
| Leisure Activities | 1 | 2018 | 221 | 0.04 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Family Relations | 1 | 2018 | 288 | 0.04 | Why? |
| Prejudice | 1 | 2018 | 245 | 0.04 | Why? |
| Depression | 1 | 2019 | 14116 | 0.04 | Why? |
| Social Discrimination | 1 | 2018 | 269 | 0.04 | Why? |
| Reference Values | 1 | 2017 | 795 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Biological Products | 2 | 2020 | 2331 | 0.03 | Why? |
| Language | 1 | 2019 | 655 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Janus Kinases | 1 | 2017 | 414 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Disease Management | 2 | 2017 | 6841 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2020 | 1463 | 0.02 | Why? |
| Cholesterol, HDL | 1 | 2011 | 439 | 0.02 | Why? |
| Employment | 1 | 2018 | 1754 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Cardiovascular Diseases | 1 | 2011 | 11497 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Multiple Sclerosis | 1 | 2018 | 2600 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |
| Animals | 1 | 2011 | 78931 | 0.00 | Why? |